Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Mobocertinib |
Synonyms | TAK-788|TAK788|AP32788|AP-32788|AP 32788 |
Therapy Description |
Exkivity (mobocertinib) inhibits EGFR and ERBB2 (HER2), with selectivity for mutant forms including EGFR exon 20 insertions, potentially resulting in growth inhibition in EGFR or ERBB2-mutant cancer cells (PMID: 33632775). Exkivity (mobocertinib) is FDA approved for use in patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations after disease progression on platinum-based chemotherapy (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Mobocertinib | Exkivity | TAK-788|TAK788|AP32788|AP-32788|AP 32788 | EGFR Inhibitor (Pan) 58 HER2 Inhibitor 39 | Exkivity (mobocertinib) inhibits EGFR and ERBB2 (HER2), with selectivity for mutant forms including EGFR exon 20 insertions, potentially resulting in growth inhibition in EGFR or ERBB2-mutant cancer cells (PMID: 33632775). Exkivity (mobocertinib) is FDA approved for use in patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations after disease progression on platinum-based chemotherapy (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02716116 | Phase Ib/II | Mobocertinib | A Trial of TAK-788 (AP32788) in Non-small Cell Lung Cancer (NSCLC) | Recruiting | USA | ITA | GBR | ESP | DEU | 4 |
NCT04129502 | Phase III | Mobocertinib Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium | TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 16 |